Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetically modified muscarinic acetylcholine receptors (mAChRs) that have minimal responsiveness to acetylcholine (ACh) but are potently and efficaciously activated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO). DREADDs have been used as tools for selectively modulating signal transduction pathways in vitro and in vivo. Recent comprehensive studies have validated how the pharmacology of a CNO-bound DREADD mirrors that of an ACh-bound wild-type (WT) mAChR. However, nothing is known about whether this equivalence extends to the allosteric modulation of DREADDs by small molecules. To address this, we investigated the actions at an M 1 DREADD of benzyl quinolone carboxylic acid (BQCA), a positive allosteric modulator of ACh binding and function that is known to behave according to a simple twostate mechanism at the WT receptor. We found that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the corresponding modulation of the AChbound WT receptor. We also found that BQCA engenders stimulus bias at the M 1 DREADD, having differential types of cooperativity depending on the signaling pathway. Furthermore, the modulation of ACh itself by BQCA at the DREADD is not compatible with the two-state model that we previously applied to the M 1 WT receptor.
Introduction
Over the last decade, chemical-genetic strategies have been applied in the generation of tools for investigating G proteincoupled receptor (GPCR) function with increasing degrees of spatial and temporal specificity. Such chemogenetically modified GPCRs include receptors activated solely by synthetic ligands (Pei et al., 2008) and designer receptors exclusively activated by designer drugs (DREADDs) (Armbruster et al., 2007) , the latter having been specifically generated using the muscarinic acetylcholine receptor (mAChR) subtypes as the model system (Armbruster et al., 2007) . These mAChR DREADDs contain two mutations of conserved orthosteric site residues (Y106C and A196G in the M 1 mAChR) that cause a loss of responsiveness to the cognate agonist acetylcholine (ACh) while engendering the ability to be potently activated by the otherwise biologically inert ligand, clozapine-N-oxide (CNO). When these mutant GPCRs are expressed in a particular tissue, the resultant biological effects observed after administration of CNO only reflect the activation of the chosen DREADD in that particular tissue. As such, DREADDs have proven to be valuable biological tools and have been expressed transgenically to investigate specific functions of several mAChRs and the physiologic consequences of their activation in vivo (Alexander et al., 2009; Guettier et al., 2009; Ferguson et al., 2011; Krashes et al., 2011; Ray et al., 2011; Sasaki et al., 2011; Garner et al., 2012) .
Recently, it has become apparent that different ligands binding to the same GPCR can stabilize specific receptor conformations that are coupled to distinct functional outcomes; a phenomenon termed "stimulus bias," "biased agonism," or "functional selectivity" (Stallaert et al., 2011) . This begs the question as to how much the action of the CNO-bound DREADD truly reflects that of the ACh-bound wild-type (WT) receptor. Fortunately, a recent rigorous investigation of multiple signaling and receptor regulatory pathways at the M 3 DREADD concluded that the results obtained from the transgenic expression of the DREADD when activated by CNO are indeed likely to mirror the actions of ACh at the WT s This article has supplemental material available at molpharm.
aspetjournals.org.
ABBREVIATIONS: ACh, acetylcholine; BQCA, benzyl quinolone carboxylic acid; CHO, Chinese hamster ovary; CNO, clozapine-N-oxide; CNS, central nervous system; DMEM, Dulbecco's modified Eagle's medium; DREADD, designer receptor exclusively activated by designer drug; FBS, fetal bovine serum; GPCR, G protein-coupled receptor; GppNHp, triphosphate; IBMX, 3-isobutyl-1-methylxanthine; IP1, inositolphosphate-1; mAChR, muscarinic acetylcholine receptor; carbamoyloxy)-2-butynyltrimethylammnonium chloride; MWC, Monod-Wyman-Changeux; NDMC, n-desmethyl-clozapine; pERK1/2, phosphorylated extracellular signal-regulated kinase; QNB, quinuclidinyl benzilate; TBPB, 1-[19-(2-methylbenzyl)-1,49-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one; WT, wild-type.
receptor (Alvarez-Curto et al., 2011) . However, there exist alternative possible utilities of DREADDs for which such vital equivalence with the WT remains undetermined; these possibilities involve the potential combination of DREADDs with small molecule allosteric modulators of GPCRs. As we previously showed using the M 4 DREADD, it is possible to use an allosteric modulator to "reactivate" the DREADD to its cognate agonist, ACh (Nawaratne et al., 2008) . A potential advantage of this approach is that the temporal specificity associated with endogenous ACh release and uptake can be retained while activating the DREADD in a spatially controlled fashion. Irrespective, the nature of allosteric modulation of CNO itself at a DREADD remains unknown, although this approach may also be considered as a means to better understand GPCR allostery in a tissue/pathway-targeted manner. An ideal requirement for addressing these issues would be an allosteric modulator that behaves in a predictable manner and does not promote stimulus bias when tested against ACh at a WT mAChR. We recently characterized the actions of such a ligand, benzyl quinolone carboxylic acid (BQCA), at the M 1 WT mAChR (Canals et al., 2012) . Specifically, BQCA displays simple receptor "state dependence," exhibiting positive cooperativity with orthosteric agonists but negative cooperativity with inverse agonists in a manner that correlates with orthosteric ligand efficacy. Importantly, the allosteric modulation of BQCA did not engender stimulus-bias at a variety of M 1 mAChR-linked signaling pathways (Canals et al., 2012) . The discovery of such a molecule thus presents an unprecedented opportunity to investigate the nature of allosteric modulation of a DREADD with regards to both the cognate receptor agonist and the synthetic activator CNO. Herein, we provide a comprehensive analysis of the allosteric interaction of BQCA with ACh, CNO, and a diverse range of M 1 mAChR ligands at multiple downstream signaling pathways linked to the M 1 WT and DREADD mAChRs. We reveal that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the ACh-bound WT receptor and that BQCA engenders stimulus bias at the M 1 DREADD.
Materials and Methods
Materials. Chinese hamster ovary (CHO) FlpIn cells and Dulbecco's modified Eagle's medium (DMEM) were purchased from Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from ThermoTrace (Melbourne, Australia). Hygromycin-B was purchased from Roche (Mannheim, Germany). [ 3 H]quinuclidinyl benzilate ([ 3 H]QNB; specific activity, 50 Ci/mmol), cAMP AlphaScreen beads, AlphaScreen reagents and Ultima gold scintillation liquid were purchased from PerkinElmer Life Sciences (Boston, MA). The SureFire cellular extracellular signal-regulated kinase (ERK1/2) assay kits were a generous gift from TGR BioSciences (Adelaide, Australia). IP-One assay kit and reagents were purchased from Cisbio (Codolet, France). Fluo-4-AM was purchased from Molecular Probes (Carlsbad, CA). All other chemicals were purchased from Sigma Aldrich (St. Louis, MO). BQCA was synthesized in house at the Monash Institute of Pharmaceutical Sciences (Parkville, Australia).
Cell Culture and Receptor Mutagenesis. The M 1 DREADD mutations [Y106C/A196G-3.33 and -5.46 , respectively, using the Ballesteros-Weinstein numbering system (Ballesteros and Weinstein, 1995) ] were generated using the QuickChange site-directed mutagenesis kit (Agilent Technologies, La Jolla, CA), following the manufacturer's instructions. CHO FlpIn cells stably expressing the M 1 WT or DREADD mAChRs were generated and maintained as described previously (Avlani et al., 2010) .
Membrane Preparation and Radioligand Binding. Membranes from CHO FlpIn cells stably expressing either M 1 WT or DREADD mAChRs were prepared as described previously (Nawaratne et al., 2008) . Radioligand binding assays were performed using 5mg and 20 mg of M 1 WT and DREADD mAChR membrane homogenates, respectively. Membranes were incubated in 1 ml binding buffer (20 mM HEPES, 100 mM NaCl, 10 mM, MgCl 2 , pH 7.4) containing 100 mM guanosine 59- [b, g-imido] ]QNB used in all subsequent heterologous competition binding assays was approximately equal to its equilibrium dissociation constant at the M 1 WT mAChR (0.13 6 0.03 nM; n 5 3). Interaction studies were performed in the absence or presence of increasing concentrations of BQCA. For all experiments, total and nonspecific binding was defined by the absence of competing ligand and the presence of 100 mM atropine, respectively. The termination of the assay and measurements of bound radioactivity were performed as described in Avlani et al. (2010) .
Extracellular Signal-Regulated Kinase 1/2 Phosphorylation Assays. Assays to measure M 1 mAChR-mediated stimulation of ERK1/2 phosphorylation were performed using the AlphaScreenbased SureFire kit (TGR Biosciences), following the manufacturer's instructions. Briefly, FlpIn CHO cells stably expressing either the M 1 WT or DREADD mAChRs were seeded into 96-well culture plates at 40,000 cells per well and allowed to adhere. Cells were then rinsed with phosphate-buffered saline and serum starved overnight at 37°C, 5% CO 2 . The following day, cells were stimulated with agonist. Initial ERK1/2 phosphorylation (pERK1/2) time course experiments were performed to determine the time of maximal ERK1/2 phosphorylation for each agonist (found to be 5 minutes for all agonists tested). The time of peak agonist response was then used for the establishment of concentration-response curves. For functional interaction studies, cells were incubated at 37°C with varying concentrations of agonist in the absence and presence of varying concentrations of BQCA, which was co-added with the agonist. In all experiments, 10% (v/v) FBS was used as positive control of pERK1/2. The reaction was terminated by removal of media and addition of lysis buffer. Samples were processed according to kit instructions. The fluorescence signal was measured using a Fusion-a plate reader (PerkinElmer Life Sciences). Data were normalized to the maximum response elicited by 10% (v/v) assay buffer containing 1 mM Fluo-4-AM for 1 hour in the dark at 37°C 5% CO 2 . After two washes with Ca 21 assay buffer, fluorescence was measured for 1.5 minutes upon the addition of agonist (or coaddition of agonist and BQCA) in a Flexstation (Molecular Devices, Sunnyvale, CA) using an excitation wavelength of 485 nm and emission wavelength of 520 nm. Data were normalized to the peak response elicited by 2 mM ionomycin.
cAMP Accumulation Assays. FlpIn CHO cells were seeded at 35,000 cells per well into 96-well culture plates and allowed to grow overnight at 37°C, 5% CO 2 . Cells were incubated with 90 ml of stimulation buffer [phenol red-free DMEM containing 0.1% (w/v) BSA, 5 mM HEPES, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), pH 7.4] for 30 minutes at 37°C, 5% CO 2 . Cells were stimulated with agonist for 30 minutes, after which the medium was removed and cells were precipitated with 100% ethanol. Ethanol was allowed to evaporate at room temperature or in a nonhumidified incubator at 37°C. After ethanol evaporation, cells were lysed with lysis buffer [0.3% Tween20, 5 mM HEPES, 0.1% (w/v) BSA]. Lysates were processed according to the AlphaScreen kit manufacturer instructions (PerkinElmer Life Sciences). The fluorescence signal was measured using a Fusion-a plate reader (PerkinElmer Life Sciences). Data were normalized to the maximum response elicited by 100 mM forskolin.
IP-One Accumulation Assays. Inositol phosphate-1 (IP 1 ) was measured using the IP-One assay kit (Cisbio), following the manufacturer's instructions. Briefly, FlpIn CHO cells were seeded into 384-well proxy-plates at 7500 cells per well and allowed to grow overnight at 37°C, 5% CO 2. The following day cells were stimulated with agonists in IP-One stimulation buffer (in the absence or presence of BQCA) and incubated for 1 hour at 37°C, 5% CO 2. IP 1 -d2 and anti-IP 1 -cryptate were prepared in IP-One lysis buffer and incubated with the cells for 1 hour at room temperature. Homogeneous time resolved fluorescence resonance energy transfer was measured in an Envision plate reader (PerkinElmer Life Sciences). Values for each sample were extrapolated from the IP 1 standard curve, and data were normalized to the maximum control response.
Data Analysis. All data were analyzed using Prism 5.0 (GraphPad, San Diego, CA). Inhibition binding curves between [ 3 H]QNB and unlabeled ligands were fitted to a one-site binding model (Motulsky, 2004) . BQCA binding-interaction studies were fitted to the following allosteric ternary complex model (Ehlert, 1988) :
where Y Concentration-response curves for the interaction between BQCA and the orthosteric ligand in the various functional signaling assays were globally fitted to the following operational model of allosterism and agonism (Leach et al., 2007) :
where E m is the maximum possible cellular response, [A] and [B] are the concentrations of orthosteric and allosteric ligands, respectively, K A and K B are the equilibrium dissociation constant of the orthosteric and allosteric ligands, respectively, t A and t B are operational measures of orthosteric and allosteric ligand efficacy (which incorporate both signal efficiency and receptor density), respectively, a is the binding cooperativity parameter between the orthosteric and allosteric ligand, and b denotes the magnitude of the allosteric effect of the modulator on the efficacy of the orthosteric agonist. In all instances, the equilibrium dissociation constant of each agonist was fixed to that determined from the binding assays. All affinity, potency, and cooperativity values are estimated as logarithms (Christopoulos, 1998) , and statistical comparisons between values were by Student's t-test. A value of P , 0.05 was considered statistically significant.
Results
Pharmacological Characterization of the M 1 WT and M 1 DREADD mAChR. To characterize the pharmacology of the M 1 DREADD in comparison with that of the M 1 WT mAChR, the binding and activation profiles of a range of ligands were examined (Supplemental Fig. 1 3 H]QNB (pK A 5 8.23 6 0.06; n 5 3, P , 0.05) compared with the WT (pK A 5 9.88 6 0.12; n 5 3), consistent with previous findings for DREADDs (Armbruster et al., 2007; Nawaratne et al., 2008) . The receptor expression level of the M 1 DREADD was not significantly different from the WT receptor (B max 5 4.90 6 0.35 versus 5.10 6 0.12 pmol/mg of protein for WT and DREADD receptors, respectively). Subsequent testing of structurally diverse ligands in equilibrium binding studies using 0.13 nM [ 3 H]QNB revealed different effects of the DREADD mutations on ligand binding depending on the nature of the ligand studied ( Fig. 1 ; Supplemental Fig. 2 ; Table 1 ). The affinities of the endogenous orthosteric agonist, ACh, and the partial agonist xanomeline were significantly reduced at the M 1 DREADD ( Fig Table 1 ). In contrast, the affinities of clozapine, its metabolite N-desmethylclozapine (NDMC), and the synthetic analog CNO, were significantly enhanced at the M 1 DREADD. Interestingly, 1-[19-(2-methylbenzyl)-1,49-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one (TBPB) and McN-A-343, which may have a "bitopic" (dual allosteric/orthosteric) mode of interaction at the mAChRs (Valant et al., 2012b) and display distinct sensitivities to residues proposed to be involved in orthosteric ligand binding (Valant et al., 2008; Jacobson et al., 2010) , showed no significant difference in their binding affinity at the M 1 WT and M 1 DREADD (Supplemental Figs. 1 and 2 ; Table 1 ). BQCA itself caused partial inhibition of [ 3 H]QNB binding both at the WT and DREADD M 1 mAChR, consistent with our previous finding of a negative cooperativity with the antagonist and a low affinity for the allosteric site on the free receptor (Canals et al., 2012) ; estimates of the pK I value from the current study were 4.15 6 0.11 and 4.05 6 0.13 for M 1 WT and DREADD mAChRs, respectively ( Fig. 1; Table 1 ).
We also investigated the ability of the different ligands to activate WT and DREADD receptors using intracellular Ca 21 mobilization as a canonical measure of M 1 mAChR activation resulting from preferential coupling to Ga q proteins. Both ACh and xanomeline displayed a significant loss of potency at the M 1 DREADD, whereas clozapine and its derivatives CNO and NDMC gained potency and/or efficacy at the M 1 DREADD ( Fig. 1; Supplemental Fig. 3 ; Table 1 ). TBPB activated the M 1 DREADD with comparable potency and efficacy to its activity at the WT receptor. However, in contrast to the unaltered binding profile at the M 1 DREADD, McN-A-343 displayed reduced potency and efficacy at this receptor (Supplemental Fig. 3 ; Table 1 ). At the M 1 WT mAChR, BQCA also behaved as a potent and efficacious allosteric agonist in its own right. However, the mutations in the M 1 DREADD caused a significant abolishment in BQCA's action, despite having no effect on its affinity (Fig. 1, C and F ; Table 1 ).
Allosteric Modulation of CNO Binding Affinity at the M 1 DREADD is Less than that of ACh at the M 1 WT mAChR. Given the previously determined functional equivalence between CNO at the DREADD and ACh at the WT mAChR (Armbruster et al., 2007; Alvarez-Curto et al., 2011) , we investigated whether such equivalence is retained in terms (Fig. 2) . BQCA substantially potentiated ACh-mediated inhibition of equilibrium binding of [ 3 H]QNB at the M 1 WT mAChR ( Fig.  2A) . A similar pattern of potentiation was observed in the interaction between CNO and BQCA at the M 1 DREADD (Fig.  2D) . However, when this potentiation was quantified by application of an allosteric ternary complex model to the data (Eq. 1; Table 2), we found that the positive binding cooperativity between ACh and BQCA at the M 1 WT mAChR (a 5 331) was significantly higher than that with CNO at the M 1 DREADD (a 5 60). Conversely, BQCA had no effects on the affinity of CNO at the M 1 WT and of ACh at the M 1 DREADD, indicating neutral binding cooperativity (Fig. 2, B and C) .
The Allosteric Interaction between ACh and BQCA is Consistent with a Two-state Mechanism at the M 1 WT but Not at the M 1 DREADD. To gain further insight into the functional modulation mediated by BQCA, we performed interaction studies using multiple signaling pathways linked to M 1 mAChR activation, namely; intracellular Ca 21 mobilization, ERK1/2 phosphorylation, cAMP and IP 1 accumulation. Figure 3 shows the interaction between ACh and BQCA at both the M 1 WT and DREADD mAChRs in the various signaling pathways. BQCA strongly potentiated the action of ACh at the M 1 WT mAChR, in addition to exhibiting agonism on its own in the two highly amplified and efficiently coupled signaling pathways, i.e., intracellular Ca 21 mobilization and ERK1/2 phosphorylation (Fig. 3, A and B) . In the cAMP accumulation pathway (where stimulus-response coupling efficiency is weak), BQCA's agonism was less pronounced, but robust potentiation of ACh was still evident (Fig. 3C) . These data were globally fitted to an operational model of allosterism (Eq. 2) to yield the parameters shown in Table 3 ; for this analysis, the binding affinity of BQCA was fixed to the pK B value determined from the binding studies (Table 1) . In agreement with our previous study (Canals et al., 2012) , BQCA displayed the highest levels of positive cooperativity (quantified by the operational ab parameter) at the pathways where the orthosteric agonist exhibited the highest degrees of signaling efficacy (quantified by the operational model t A parameter), as would be expected if the allostery was operative within a simple two-state mechanism. However, when analogous interaction studies between ACh and BQCA were performed at the M 1 DREADD, we noted that BQCA robustly enhanced the potency of ACh in both the Ca 21 mobilization and pERK1/2 pathways (Fig. 3, D and E) despite having no effect on ACh binding affinity. Additionally, in experiments measuring stimulation of intracellular cAMP production, where ACh showed no agonistic activity at the DREADD, BQCA was able to partially rescue its signaling efficacy (Fig.  3F) . Although BQCA displayed high positive cooperativity with ACh at the M 1 DREADD, this cooperativity did not track with the degree of agonist efficacy across the pathways, in contrast to what was observed at the M 1 WT mAChR (Table 3 ; see correlation analysis below), suggesting that the two state behavior of BQCA versus ACh may not be maintained at the M 1 DREADD.
BQCA Engenders Biased Allosteric Modulation of CNO at the M 1 DREADD. Subsequent experiments focused on the functional modulation by BQCA of CNO. In contrast to the large and positive cooperativity seen between ACh and BQCA in the Ca 21 mobilization pathway at the M 1 WT mAChR ( Fig. 3A; Table 3 ), BQCA had a minimal effect on the action of CNO at the M 1 DREADD in the same pathway (Fig.  4A) . To rule out the possibility that this observation resulted from potential hemi-equilibrium conditions in the Ca 21 mobilization assay, we repeated the same experiment in an IP 1 accumulation assay. Again, BQCA did not potentiate the action of CNO in this latter assay (Fig. 4B) . Application of the operational model to the data yielded the estimates shown in Table 4 . Given that the positive binding cooperativity (a value) between CNO and BQCA was 60, our results suggest that BQCA actually has a negative effect on the signaling efficacy of CNO, with estimated values of b 5 0.03 and b 5 0.13 for the Ca 21 mobilization and IP 1 assays, respectively. In contrast, BQCA enhanced the action of CNO in the ERK1/2 phosphorylation pathway (Fig. 4C ) with a composite cooperativity (ab) of 41 (Table 4) . Given the similar cooperativity estimated from binding studies (a 5 60), this indicates the presence of essentially neutral modulation at the level of signaling efficacy (b).
Collectively, as summarized in Fig. 5 , these findings suggest that BQCA engenders stimulus bias at the M 1 DREADD by demonstrating neutral functional modulation in one pathway (ERK1/2 phosphorylation) and negative functional modulation in another (Ca 21 mobilization). Despite the overall large positive cooperativity between BQCA and CNO at the M 1 DREADD in the pERK1/2 pathway, it is still significantly smaller than the cooperativity between ACh and BQCA at both the M 1 WT and DREADD mAChRs in the same signaling pathway. When this interaction was examined in the cAMP pathway, BQCA positively modulated the potency of CNO but had negative effects on its efficacy (Fig. 4D) . This broad spectrum of pharmacological behaviors at the M 1 DREADD indicates that the actions of BQCA do not conform to a simple "two-state" model, in contrast to its behavior at the M 1 WT mAChR. Fig. 4A ; Table 2 ). Furthermore, the stimulus bias of BQCA at the M 1 DREADD was again demonstrated by its interaction with NDMC in the functional signaling pathways, whereby it displayed negative efficacy modulation of NDMC in the Ca 21 mobilization pathway, but neutral modulation of NDMC efficacy in the ERK1/2 phosphorylation pathway (Supplemental Fig. 4 , B and C; Supplemental Table 1 ). Similar to the CNO interaction studies, BQCA caused a reduction in the efficacy of NDMC in the cAMP pathway (Supplemental 4D ). These results demonstrate that the biased allosteric behavior of BQCA at the M 1 DREADD is likely to be resulting from the conformations stabilized by the clozapine derivatives CNO and NDMC at this receptor, because the same pattern of modulatory bias across signaling pathways at the M 1 DREADD was not observed in the interaction of BQCA with ACh (Fig. 3, D-F) . Subsequently, we extended these studies to the other mAChR ligands. The data from each ligand-BQCA interaction experiment were globally fitted to the operational model of allosterism (eq. 2), and the relationship between the parameters log t A and log ab was examined for each set of ligand interactions (Supplemental Table 2 ). As shown in Fig. 6 , A and B, a significant correlation between the parameters log t A and log ab can be observed at the M 1 WT mAChR in both the Ca 21 mobilization (Pearson's r 2 5 0.736; P 5 0.01) and pERK1/2 pathways (Pearson's r 2 5 0.625; P 5 0.03), providing further evidence for the allosteric two-state behavior of BQCA at this receptor. When the same set of ligand-BQCA interactions studies were performed at the M 1 DREADD and analyzed in the same manner, no significant correlation was observed between the parameters log t A and log ab in both the Ca 21 mobilization (Pearson's r 2 5 0.004; P 5 0.89) and pERK1/2 pathways (Pearson's r 2 5 0.264; P 5 0.24) (Fig. 6 , C and D). These results therefore suggest that the two-state model proposed for the mechanism of action of BQCA at the WT mAChR is applicable beyond its interaction with ACh, but is not applicable at the M 1 DREADD.
Discussion
Recent studies have provided compelling evidence that the CNO-bound DREADD mAChR retains functional equivalence with the ACh-bound WT mAChR, thus validating the chemogenetically modified DREADD as a powerful tool for probing GPCR signaling in a highly specific manner (Alexander et al., 2009; Guettier et al., 2009; Alvarez-Curto et al., 2011; Krashes et al., 2011 ). In the current study, we extended this question to the phenomenon of small molecule allostery and explored the behavior of BQCA in its interaction with a number of structurally and functionally diverse ligands at the M 1 DREADD. This modulator was chosen because we recently demonstrated that its actions at the M 1 WT mAChR can be reconciled within a two-state receptor model, akin to that applied to many ion channels, thus representing the simplest case of allosteric modulation with clear, predictable properties (Canals et al., 2012) . We reveal that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the corresponding modulation of the ACh-bound WT receptor. In addition, we find that BQCA engenders stimulus bias at the M 1 DREADD, most strikingly by behaving as a neutral allosteric modulator of CNO efficacy in the pERK1/2 pathway while having negative modulation in the Ca 21 mobilization and IP 1 pathways. Moreover, the modulation of ACh itself by BQCA at the DREADD is also not compatible with a simple Log t A 2.81 6 0.04 2.65 6 0.10 2.12 6 0.05 Log t B (t B ) 0.38 6 0.04 (2.4) 0.44 6 0.17 (2.8) 0.41 6 0.07 (2.6) Log ab (ab) 0.30 6 0.29 (2)* 1.61 6 0.22 (41)* 0.88 6 0.21 (7.5) * Significantly different (P , 0.05), two-tailed Students t-test, from the corresponding value at the M 1 WT in Table 3 . two-state model that we have applied to the M 1 WT. These findings indicate that the behavior of the DREADD with respect to allosteric modulation is a manifestation of multiple, distinct, receptor conformations.
Because mAChR subtypes are characterized by a very high degree of amino acid sequence conservation within the orthosteric (ACh) binding site (Wess et al., 2003) , previous attempts to target the M 1 mAChR have failed due to unwanted side effects that result from their lack of subtype selectivity (Conn et al., 2009 ). An alternative approach to achieve subtype selectivity is to develop ligands that target allosteric sites that are less conserved between subtypes (Christopoulos, 2002) . BQCA is one such compound that has high subtype selectivity for the M 1 mAChR. Importantly, the modulator exhibits both in vitro and in vivo efficacy as a potentiator of ACh affinity and signaling Shirey et al., 2009; Canals et al., 2012) . Allosteric modulators such as BQCA represent not only potential therapeutics, but are also useful tools to study the selective activation of GPCRs both in vitro and in vivo. Another powerful method for generating tools to study receptor activity in a defined spatial and temporal manner is the chemogenetic approach, as exemplified by the generation of DREADDs (Conklin, 2007) . Given the potential offered by the combination of these two approaches to interrogate M 1 mAChR function, it is essential to perform a detailed pharmacological characterization of this mutant receptor. Although several studies have transgenically expressed the DREADD receptors in animal models and investigated the physiologic consequence of activating them in vivo (Alexander et al., 2009; Guettier et al., 2009; Krashes et al., 2011; Ferguson et al., 2011; Ray et al., 2011; Sasaki et al., 2011; Garner et al., 2012) , no study has thus far studied allosteric or bitopic ligands at these mutant receptors. By using ACh and xanomeline as orthosteric ligands, TBPB and McN-A-343 as ligands that possibly have a bitopic mode of interaction with the mAChRs (Valant et al., 2008; Jacobson et al., 2010) , CNO as the orthosteric ligand at the M 1 DREADD and its analogs clozapine and NDMC, we identified different profiles of receptor binding and activation at the M 1 DREADD that suggest multiple modes of receptor engagement ( Fig. 1; Supplemental Figs. 1-3 ; Table 1 ). As expected from prior studies using DREADDs, the affinity and potency of ACh and xanomeline were reduced, while CNO and its Table 2 ) from the composite estimates determined from the functional assays (Fig. 3, A Table 2 ) for the functional allosteric interactions between BQCA and each of the ligands. structural analogs, NDMC and clozapine, showed significant gains in these parameters. Interestingly, we reveal for the first time that the affinity and potency of TBPB was unaffected by the M 1 DREADD mutations. Unlike TBPB, however, McN-A-343, a partial M 1 mAChR agonist that has been shown to be bitopic at the M 2 mAChR (Valant et al., 2008) , displayed reduced potency and efficacy at the M 1 DREADD that was not due to a loss of binding affinity (Supplemental Figs. 2 and 3 ; Table 1 ), indicating that the DREADD mutations had a specific effect on the ability of McN-A-343 to mediate receptor transition into an active state; this appears not to be the case for TBPB.
In addition to providing insights into the nature of putative bitopic ligand interactions on the DREADDs, the key finding of the current study was the consequences of allosteric modulation of both the cognate and synthetic agonists in this system. In agreement with our previous study (Canals et al., 2012) , BQCA exhibited key hallmarks of allostery within a two-state system at the WT M 1 mAChR, including positive or negative modulation of orthosteric ligand activity depending on the nature of the orthosteric ligand (i.e., positive or inverse agonist) and different strengths of cooperativity depending on the intrinsic efficacy of the orthosteric ligand and the magnitude of stimulus-response coupling of the studied signal pathway. It can, of course, be questioned as to how an allosteric modulator can behave in a manner consistent with a two-state model at GPCRs given that these receptors adopt a larger spectrum of biologically active states, a prerequisite, in fact, for biased signaling (Vaidehi and Kenakin, 2010; Mary et al., 2012) . This can be reconciled within a model whereby the modulator changes the abundance, but not the quality/nature, of different microstates that govern receptor activity; an overall change in abundance of active microstates in one direction relative to "inactive" microstates would still appear, at a macroscopic level, as a "two-state" system. In contrast, a change in the nature or quality of the microstates, in addition to their abundance, would manifest as biased modulation. In this regard, BQCA is a relatively unique, but extremely useful tool compound for probing allosteric principles compared with the more complex behaviors of numerous allosteric modulators at different GPCR families that appear to promote pathway-biased modulation to various extents (Mathiesen et al., 2005; Maillet et al., 2007; Marlo et al., 2009; Stewart et al., 2010; Davey et al., 2012; Valant et al., 2012a) At first glance, it may also be argued that the functional equivalence between ACh at the WT M 1 mAChR and CNO at the M 1 DREADD is retained with regards to the effects of BQCA in a two-state model. Specifically, the higher degree of positive cooperativity between the modulator and ACh at the WT M 1 mAChR, relative to its effects on CNO at the M 1 DREADD, would be expected, given that ACh displays higher efficacy at the WT than CNO at the DREADD (compare, for instance, the log t A values for ACh at the WT M 1 mAChR in Table 3 to the log t A values for CNO at the M 1 DREADD in Table 4 ). However, there were two key lines of evidence arguing against this conformational equivalence with regards to allosteric modulation of the two receptors. First, the degree of cooperativity between various orthosteric agonists and BQCA at the DREADD did not track with the degree of efficacy displayed by the agonists, which is a key expectation of the two-state model and is generally evident at the WT M 1 mAChR (Fig. 6) . Second, and more strikingly, the interaction between BQCA and CNO at the DREADD was characterized by positive, neutral, or negative modulation of CNO efficacy, depending on the pathway being monitored. A similar pattern of BQCA allosteric modulation was observed when the functional interaction studies were performed with NDMC instead of CNO (Supplemental Fig. 4 ; Supplemental Table 1 ). These results suggest that the pattern of biased modulation is likely to result from a unique receptor conformation stabilized by clozapine derivatives in combination with BQCA at the M 1 DREADD that is distinct from that stabilized by ACh and BQCA at the M 1 WT mAChR. The recent advances in GPCR (and mAChR particularly) structural biology (Haga et al., 2012; Kruse et al., 2012) , together with novel biophysical approaches to study receptor conformations, offer an ideal platform to compare the M 1 WT and M 1 DREADD from a structural perspective and therefore to provide mechanistic insight into the differences observed in our studies 
